West Pharmaceutical Services, Inc. $WST Shares Acquired by Coldstream Capital Management Inc.

Coldstream Capital Management Inc. increased its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 19.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,264 shares of the medical instruments supplier’s stock after buying an additional 366 shares during the period. Coldstream Capital Management Inc.’s holdings in West Pharmaceutical Services were worth $495,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. SYM FINANCIAL Corp increased its position in shares of West Pharmaceutical Services by 5.1% in the 2nd quarter. SYM FINANCIAL Corp now owns 1,027 shares of the medical instruments supplier’s stock worth $225,000 after purchasing an additional 50 shares during the last quarter. Parkside Financial Bank & Trust grew its stake in West Pharmaceutical Services by 4.0% in the second quarter. Parkside Financial Bank & Trust now owns 1,318 shares of the medical instruments supplier’s stock worth $288,000 after purchasing an additional 51 shares in the last quarter. MJP Associates Inc. ADV grew its stake in West Pharmaceutical Services by 2.7% in the second quarter. MJP Associates Inc. ADV now owns 1,970 shares of the medical instruments supplier’s stock worth $431,000 after purchasing an additional 52 shares in the last quarter. Horizon Investments LLC increased its holdings in West Pharmaceutical Services by 5.8% in the first quarter. Horizon Investments LLC now owns 1,048 shares of the medical instruments supplier’s stock valued at $234,000 after buying an additional 57 shares during the last quarter. Finally, Pallas Capital Advisors LLC raised its stake in West Pharmaceutical Services by 1.0% during the second quarter. Pallas Capital Advisors LLC now owns 6,333 shares of the medical instruments supplier’s stock valued at $1,386,000 after buying an additional 62 shares in the last quarter. 93.90% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently commented on WST. Evercore ISI lifted their target price on West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “outperform” rating in a research report on Thursday, October 23rd. Deutsche Bank Aktiengesellschaft set a $345.00 price objective on shares of West Pharmaceutical Services and gave the stock a “buy” rating in a report on Friday, October 24th. Rothschild & Co Redburn initiated coverage on shares of West Pharmaceutical Services in a research note on Monday, September 15th. They set a “buy” rating and a $311.00 target price for the company. TD Cowen assumed coverage on shares of West Pharmaceutical Services in a research report on Wednesday, October 29th. They issued a “buy” rating and a $350.00 price target on the stock. Finally, Cowen assumed coverage on shares of West Pharmaceutical Services in a report on Wednesday, October 29th. They issued a “buy” rating for the company. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $349.20.

West Pharmaceutical Services Stock Performance

WST opened at $277.36 on Friday. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.07. The business’s 50 day moving average is $270.98 and its 200-day moving average is $245.14. The stock has a market cap of $19.95 billion, a PE ratio of 41.09, a price-to-earnings-growth ratio of 4.09 and a beta of 1.08. West Pharmaceutical Services, Inc. has a twelve month low of $187.43 and a twelve month high of $348.90.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 EPS for the quarter, beating the consensus estimate of $1.67 by $0.29. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.The firm had revenue of $804.60 million for the quarter, compared to analysts’ expectations of $788.42 million. During the same period last year, the firm earned $1.85 EPS. The firm’s revenue was up 7.7% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. On average, analysts predict that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current year.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.